- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03326648
The Role of Muscle Protein Breakdown in the Regulation of Muscle Quality in Frail Elderly Individuals
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aging is associated with impaired skeletal muscle function. This is evident not only by a reduced capacity to generate force and power at the whole muscle level, but also by a decline in individual muscle fiber contraction velocity and force generation. Combined with muscle atrophy, these changes lead to reduced muscle strength and quality and loss off physical function with age. Clinically, muscle quality may be a better indicator of overall functional capacity than absolute muscle strength. Thus, identifying the mechanisms underlying the age-related loss of muscle quality is of high relevance for the prevention of functional impairment with aging. The explanation for the loss of muscle quality with aging seems to be multifactorial, with alterations in voluntary muscle activation, muscle architecture, fat infiltration and impaired contractile properties of single muscle fibers being likely contributors. Single fiber specific force seems to be related to myosin heavy chain (MHC) content, which is thought to reflect the number of available cross-bridges. The reduction of single fiber specific force with aging may thus be a consequence of reduced synthesis of MHC and/or increased concentration of non-contractile tissue (e.g. intramyocellular lipids).
Some studies in mice also indicate attenuated activity in some of the pathways responsible for degradation of muscle proteins with aging (especially autophagy). As a result, damaged proteins and organelles are not removed as effectively as they should, which could ultimately compromise the muscle's ability to produce force. In addition, reduced efficiency of mitophagy and lipophagy (two specific forms of autophagy), may indirectly affect single fiber specific force, through oxidative damage by reactive oxygen species (ROS) and increased levels of intramyocellular lipids, respectively. Although animal studies indicate attenuated autophagic function, exercise seems to restore the activity in this pathway. Whether this also is the case in humans is unknown. Thus, the purpose of this study is to investigate how the different factors contributing to reduced muscle quality in frail elderly individuals, with emphasis on the relationship between muscle quality and autophagy, may be counteracted by a specific strength training program targeting muscle quality and muscle mass.
In this randomized controlled trial the investigators will aim to recruit frail elderly individuals, as muscle quality is shown to be low in this population. As a consequence, the potential for improved muscle quality is expected to be large. Subjects will be randomized to two groups; one group performing strength training twice a week for 10 weeks in addition to receiving daily protein supplementation. The other group will only receive the protein supplement. Several tests will be performed before and after the intervention period, including a test day where a biopsy is obtained both at rest, and 2.5 hours following strength training + protein supplementation or protein supplementation only. This will provide information about the regulation of muscle protein breakdown in a resting state, following protein intake and following strength training in combination with protein intake. As this will be done both before and after the training period, it will also provide information on how long-term strength training affects the activity in these systems.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Oslo, Norway, 0863
- Norwegian School of Sport Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age > 65
- Frail or pre-frail according to the Fried Frailty Criteria or Short Physical Performance Battery (SPPB) score <6.
- Mini Mental State Examination score > 18
Exclusion Criteria:
- Diseases or injuries contraindicating participation
- Lactose intolerance
- Allergy to milk
- Allergy towards local anesthetics (xylocain)
- Use of anticoagulants that cannot be discontinued prior to the muscle biopsy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Strength training + protein supplement
Two sessions of strength training each week in addition to daily protein supplementation for 10 weeks.
|
Heavy load strength training performed twice a week for 10 weeks.
Other Names:
Dietary protein supplement (protein-enriched milk with 0,2 % fat).
0,33 l each day for 10 weeks.
|
EXPERIMENTAL: Protein supplement
Daily protein supplementation for 10 weeks.
|
Dietary protein supplement (protein-enriched milk with 0,2 % fat).
0,33 l each day for 10 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Single fiber specific force
Time Frame: Change from baseline at 10 weeks
|
A measure of muscle quality at the single fiber level.
Biopsies obtained from m. Vastus Lateralis
|
Change from baseline at 10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Lean mass
Time Frame: Change from baseline at 10 weeks
|
Measured by a Dual-energy X-ray absorptiometry (DXA) scan
|
Change from baseline at 10 weeks
|
Fat mass
Time Frame: Change from baseline at 10 weeks
|
Measured by a Dual-energy X-ray absorptiometry (DXA) scan
|
Change from baseline at 10 weeks
|
Bone mineral density
Time Frame: Change from baseline at 10 weeks
|
Measured by a Dual-energy X-ray absorptiometry (DXA) scan
|
Change from baseline at 10 weeks
|
Muscle strength of m. quadriceps
Time Frame: Change from baseline at 10 weeks
|
Maximal isometric and dynamic muscle strength of m. quadriceps
|
Change from baseline at 10 weeks
|
Muscle size of m. quadriceps
Time Frame: Change from baseline at 10 weeks
|
Cross-sectional area of m. quadriceps measured by a Computed Tomography scan
|
Change from baseline at 10 weeks
|
Fat infiltration of m. quadriceps
Time Frame: Change from baseline at 10 weeks
|
Fat infiltration of m. quadriceps measured by a Computed Tomography scan
|
Change from baseline at 10 weeks
|
Muscle activation
Time Frame: Change from baseline at 10 weeks
|
Voluntary activation level during a maximal isometric knee extension using the interpolated twitch technique
|
Change from baseline at 10 weeks
|
Fractional Breakdown Rate
Time Frame: Measured over the last 14 days of the intervention period
|
Measurement of fractional breakdown rate by the use of orally provided Deuterium Oxide, biopsies and blood samples
|
Measured over the last 14 days of the intervention period
|
m. Vastus Lateralis thickness
Time Frame: Change from baseline at 10 weeks
|
Measured by ultrasound
|
Change from baseline at 10 weeks
|
Chair stand performance
Time Frame: Change from baseline at 10 weeks
|
Time (sec) to stand up from a chair five times
|
Change from baseline at 10 weeks
|
Habitual gait velocity
Time Frame: Change from baseline at 10 weeks
|
Time (sec) to walk 6 meters at habitual gait velocity
|
Change from baseline at 10 weeks
|
Maximal gait velocity
Time Frame: Change from baseline at 10 weeks
|
Time (sec) to walk 6 meters as fast as possible
|
Change from baseline at 10 weeks
|
Level/cellular location of Microtubule-associated protein 1A/1B-light chain 3 (LC3)
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Level/cellular location of p62/Sequestosome-1
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Level/cellular location of Lysosome-associated membrane glycoprotein 2 (LAMP2)
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Level/cellular location of forkhead box O3 (FOXO3a)
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Phosphorylation status and total level of ribosomal protein S6 kinase beta-1(P70S6K)
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Phosphorylation status and total level of eukaryotic elongation factor 2 (eEF-2)
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Phosphorylation status and total level of eukaryotic translation initiation factor 4E-binding protein 1 (4EBP-1)
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Level/cellular location of muscle RING-finger protein-1 (Murf-1)
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Level/cellular location of ubiquitin (Ub)
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Blood serum glucose
Time Frame: Change from baseline at 10 weeks
|
Fasted
|
Change from baseline at 10 weeks
|
Blood serum insulin
Time Frame: Change from baseline at 10 weeks
|
Fasted
|
Change from baseline at 10 weeks
|
Blood plasma Hemoglobin A1c (HbA1c)
Time Frame: Change from baseline at 10 weeks
|
Fasted
|
Change from baseline at 10 weeks
|
Blood serum Triglycerides
Time Frame: Change from baseline at 10 weeks
|
Fasted
|
Change from baseline at 10 weeks
|
Blood serum High-density lipoproteins (HDL)
Time Frame: Change from baseline at 10 weeks
|
Fasted
|
Change from baseline at 10 weeks
|
Blood serum Low-density lipoproteins (LDL)
Time Frame: Change from baseline at 10 weeks
|
Fasted
|
Change from baseline at 10 weeks
|
Blood serum C-reactive protein (CRP)
Time Frame: Change from baseline at 10 weeks
|
Fasted
|
Change from baseline at 10 weeks
|
forkhead box protein O3 (FOXO3A) mRNA
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
forkhead box protein O1 (FOXO1) mRNA mRNA
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
hepatocyte growth factor (HGF) mRNA
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
insulin-like growth factor I (IGF1) mRNA
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
myostatin (MSTN) mRNA
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
E3 ubiquitin-protein ligase TRIM63 (TRIM63) mRNA
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
p62/Sequestosome-1 mRNA
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
muscle RING-finger protein-1 (Murf-1) protein 1 (4EBP-1) mRNA
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Atrogin1 mRNA
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Microtubule-associated protein 1A/1B-light chain 3 (LC3) mRNA
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
BCL2/adenovirus E1B interacting protein 3 (BNIP3) mRNA
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
PTEN-induced putative kinase 1 (PINK1) mRNA
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
TNF receptor associated factor 6 (TRAF6) mRNA
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
transcription factor EB (Tfeb) mRNA
Time Frame: Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Biopsies from m. Vastus Lateralis analyzed by western blot
|
Before and 2.5 hours after acute training session both at baseline and after 10 weeks
|
Intramyocellular lipids
Time Frame: Change from baseline at 10 weeks
|
Oil-Red-O staining of muscle sections.
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
|
Change from baseline at 10 weeks
|
Muscle fiber type distribution
Time Frame: Change from baseline at 10 weeks
|
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
|
Change from baseline at 10 weeks
|
Muscle fiber cross-sectional area
Time Frame: Change from baseline at 10 weeks
|
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
|
Change from baseline at 10 weeks
|
Muscle satellite cells
Time Frame: Change from baseline at 10 weeks
|
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
|
Change from baseline at 10 weeks
|
Myonuclei
Time Frame: Change from baseline at 10 weeks
|
Biopsy from m. Vastus Lateralis analyzed by immunohistochemistry
|
Change from baseline at 10 weeks
|
Myonuclei number
Time Frame: Change from baseline at 10 weeks
|
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
|
Change from baseline at 10 weeks
|
Myonuclei location
Time Frame: Change from baseline at 10 weeks
|
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
|
Change from baseline at 10 weeks
|
Amount of mitochondria
Time Frame: Change from baseline at 10 weeks
|
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
|
Change from baseline at 10 weeks
|
Location of mitochondria
Time Frame: Change from baseline at 10 weeks
|
Biopsy from m. Vastus Lateralis analyzed by confocal microscopy
|
Change from baseline at 10 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- STAS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcopenia
-
University of Texas at AustinNot yet recruitingExercise Training and SarcopeniaUnited States
-
Centre Hospitalier Universitaire DijonCompleted
-
Creighton UniversityUniversity of NebraskaRecruiting
-
University Hospital, CaenCompleted
-
University of NottinghamUniversity of OxfordRecruitingMuscle Atrophy | Age-Related SarcopeniaUnited Kingdom
-
Tufts UniversityNational Institute on Aging (NIA)CompletedMuscle Loss | Age-Related SarcopeniaUnited States
-
China Medical University HospitalCompleted
-
King's College LondonCo-sponsor: Guy's and St Thomas' NHS Foundation TrustCompletedFrailty | Sarcopenia | Age-Related SarcopeniaUnited Kingdom
-
Norwegian School of Sport SciencesOslo University HospitalNot yet recruitingHealthy Aging | Testosterone Deficiency | Age-Related Sarcopenia
-
Ningbo Medical Center Lihuili HospitalCompletedHemodialysis Patients With SarcopeniaChina
Clinical Trials on Strength training
-
University of AarhusUnknownOsteoarthritis, KneeDenmark
-
University of FloridaCompleted
-
Universidad Autónoma de Manizales, ColombiaCompletedFemale | Volleyball | PlayerColombia
-
Norwegian University of Science and TechnologyCompleted
-
Christian DallCompletedHeart Failure | Ischemic Heart Disease | Heart Transplant RecipientsDenmark
-
Isra UniversityCompleted
-
Lislei Jorge PatrizziCompleted
-
Eunice Kennedy Shriver National Institute of Child...Shriners Hospitals for Children; University of DelawareUnknownSpastic Diplegic Cerebral PalsyUnited States
-
Vrije Universiteit BrusselRecruitingHealthy Aged VolunteersBelgium
-
University of GiessenHannover Medical SchoolUnknownType 2 DiabetesGermany